Vous avez cherché: hyperlactatæmi (Danois - Anglais)

5 behandling med nukleosidanaloger bør stoppes i tilfælde af symptomatisk hyperlactatæmi og metabolisk acidose/ lactacidose, fremadskridende hepatomegali eller hurtigt stigende aminotransferaseniveauer.
5 treatment with nucleoside analogues should be discontinued in the setting of symptomatic hyperlactatemia and metabolic/ lactic acidosis, progressive hepatomegaly, or rapidly elevating aminotransferase levels.

antiretroviral kombinationsbehandling er forbundet med metaboliske abnormiteter såsom hypertriglyceridæmi, hypercholesterolæmi, insulinresistens og hyperglykæmi og hyperlactatæmi (se afsnit 4. 4).
combination antiretroviral therapy has been associated with metabolic abnormalities such as hypertriglyceridaemia, hypercholesterolaemia, insulin resistance, hyperglycaemia and hyperlactataemia (see section 4.4).

109 kombinationsbehandling med antiretrovirale lægemidler er associeret med metaboliske abnormiteter såsom hypertriglyceridæmi, hypercholesterolæmi, insulinresistens, hyperglycæmi og hyperlactatæmi (se afsnit 4. 4) .
combination antiretroviral therapy has been associated with metabolic abnormalities such as hypertriglyceridaemia, hypercholesterolaemia, insulin resistance, hyperglycaemia and hyperlactataemia (see section 4.4) .

tidlige symptomer (symptomatisk hyperlactatæmi) omfatter lette fordøjelsessymptomer (kvalme, opkastning og abdominalsmerter), uspecifik utilpashed, appetitløshed, vægttab, respiratoriske symptomer (hurtigt åndedræt og/ eller dybe indåndinger) eller neurologiske symptomer (herunder muskelsvaghed).
early symptoms (symptomatic hyperlactatemia) include benign digestive symptoms (nausea, vomiting and abdominal pain), non-specific malaise, loss of appetite, weight loss, respiratory symptoms (rapid and/ or deep breathing) or neurological symptoms (including motor weakness).